Skip to main content
Clinical Trials/NCT05414331
NCT05414331
Terminated
Not Applicable

WithDRawal Impact Of Postoperative Beta-Blocker

Yale University1 site in 1 country43 target enrollmentNovember 4, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Bypass
Sponsor
Yale University
Enrollment
43
Locations
1
Primary Endpoint
Peak oxygen consumption (VO2 max) to measure cardiorespiratory fitness
Status
Terminated
Last Updated
last year

Overview

Brief Summary

The investigators will evaluate the impact of withdrawing beta-blocker medication after coronary artery bypass surgery with this randomized controlled trial.

Detailed Description

Aim 1: The primary aim is to evaluate the impact of withdrawing BB on exercise capacity (peak oxygen consumption, VO2 max) in patients who underwent CABG. The investigators hypothesize that withdrawing BB 1 month after CABG will improve exercise capacity 2 months after CABG. Aim 2: The secondary objectives are to evaluate the impact of withdrawing BB on a MACCE (major adverse cardiac and cerebrovascular event) and fatigue-related symptoms in patients who underwent CABG. The investigators hypothesize that withdrawing BB after CABG for 1 year will be non-inferior to continuing BB in terms of MACCE incidence.

Registry
clinicaltrials.gov
Start Date
November 4, 2022
End Date
May 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants who underwent coronary artery bypass graft(CABG) surgery at Yale New Haven Hospital who presented to 1-month postoperative visit
  • ejection fraction \>50%, and in sinus rhythm at the time of hospital discharge or enrollment.

Exclusion Criteria

  • those who underwent combined valve + CABG surgery or aorta + CABG surgery.

Outcomes

Primary Outcomes

Peak oxygen consumption (VO2 max) to measure cardiorespiratory fitness

Time Frame: 1 month

Peak oxygen measured in ml/kg/min consumption will be measured on CPET 1 month after randomization and be compared controls. This is an important measure of exercise capacity, which has been shown to decrease in other population when on beta-blocker. The higher the measure, the better with measures greater than 12.3 ml/kg/min as positive.

Secondary Outcomes

  • Change in fatigue measured using the Fatigue Assessment Scale (FAS)(baseline and 3 months)
  • Change in activity level measured using the Veterans Specific Activity Questionnaire(VSAQ)(baseline and 3 months)
  • Adherence to medication and adjudication of endpoint(12 months)
  • Change in vertigo symptoms measured using the Vertigo Symptom Scale-short form(baseline and 3 months)

Study Sites (1)

Loading locations...

Similar Trials